Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Mangoceuticals (MGRX) Operating Expenses (2023 - 2025)

Mangoceuticals' Operating Expenses history spans 3 years, with the latest figure at $415214.0 for Q4 2025.

  • On a quarterly basis, Operating Expenses fell 76.38% to $415214.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $18.3 million, a 118.9% increase, with the full-year FY2025 number at $18.3 million, up 118.9% from a year prior.
  • Operating Expenses hit $415214.0 in Q4 2025 for Mangoceuticals, down from $7.6 million in the prior quarter.
  • Over the last five years, Operating Expenses for MGRX hit a ceiling of $7.6 million in Q3 2025 and a floor of $415214.0 in Q4 2025.
  • Historically, Operating Expenses has averaged $3.0 million across 3 years, with a median of $2.4 million in 2023.
  • The widest YoY moves for Operating Expenses: up 312.54% in 2025, down 76.38% in 2025.
  • Tracing MGRX's Operating Expenses over 3 years: stood at $2.7 million in 2023, then plummeted by 35.15% to $1.8 million in 2024, then plummeted by 76.38% to $415214.0 in 2025.
  • Business Quant data shows Operating Expenses for MGRX at $415214.0 in Q4 2025, $7.6 million in Q3 2025, and $5.4 million in Q2 2025.